Edwards Lifesciences Corporatio (EW) Stock Price & How to Invest

Edwards Lifesciences designs and sells devices that treat structural heart disease, conditions where the heart's valves are damaged or diseased. Its largest business is TAVR, a minimally invasive procedure that replaces a narrowed aortic valve with the SAPIEN valve delivered through a catheter rather than open-heart surgery; TAVR generated about $4.49 billion in 2025, roughly three-quarters of company sales. The company also sells transcatheter mitral and tricuspid therapies (TMTT) such as the PASCAL repair system, EVOQUE tricuspid valve, and SAPIEN M3 mitral system, plus traditional surgical heart valves and supporting technologies. Edwards makes money by selling these high-margin implantable devices to hospitals worldwide, supported by clinical evidence and physician training that reinforce its leadership.

Edwards was spun off from Baxter International in 2000 and became a pure-play structural heart company in 2024 when it divested its Critical Care monitoring business to Becton Dickinson (BD) for roughly $4.2 billion, sharpening its focus on transcatheter heart valves. Recent developments include the EARLY TAVR trial supporting treatment of asymptomatic severe aortic stenosis patients, with Edwards working toward an expanded FDA label, and about $1.2 billion of acquisitions (JenaValve for aortic regurgitation and Endotronix for heart-failure monitoring). TMTT grew more than 56% in 2025 to about $551 million, and the company has returned cash through share buybacks rather than a dividend.

Edwards faces several headwinds at once. TAVR growth has decelerated as the aortic-stenosis market matures, and competition from Medtronic's Evolut platform and Abbott's Navitor could erode share even after Boston Scientific's exit. Much of the business depends on favorable reimbursement and FDA decisions, so a delayed or narrowed label expansion (such as for asymptomatic patients) would hurt the growth story. The stock typically trades at a premium multiple, often well above the broad market, which leaves little margin for error if results disappoint. Finally, integrating acquisitions like JenaValve and Endotronix carries execution risk and may pressure near-term margins before the pipeline pays off.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Edwards Lifesciences Corporatio's investor relations page or your broker.

• Total revenue (FY2025): ~$6.07 billion, up ~11.5%
• TAVR sales (FY2025): ~$4.49 billion, up ~9.3%
• TMTT growth (FY2025): ~+56%, to ~$551 million
• Adjusted EPS (FY2025): ~$2.56 to $2.62 range
• Gross margin: ~78%
• Market cap: ~$48 to $52 billion
• P/E ratio: ~36x to 49x (varies by basis)

Reading a high-quality medtech like Edwards means weighing durable growth and very high gross margins against a premium valuation. The market has historically paid a P/E well above the broad market for Edwards because of its structural-heart leadership and recurring procedure-driven demand. That premium cuts both ways: when growth stays strong the multiple looks justified, but any deceleration in TAVR or a TMTT stumble can compress the multiple quickly. Because Edwards pays no dividend, total return depends on revenue and earnings growth plus buybacks rather than income.

There are three common ways to get EW exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so EW sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where EW fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Edwards Lifesciences is the dominant player in structural heart therapy, anchored by its market-leading SAPIEN TAVR franchise and a rapidly scaling transcatheter mitral and tricuspid business. It tends to behave like a large-cap, high-quality medtech compound: durable double-digit-ish growth, very high gross margins, and a premium multiple that makes the stock sensitive to any sign of decelerating growth.

Whether EW is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is EW a buy?, and where the stock could go from here in the EW stock forecast.

For income investors, whether EW pays a dividend and how the payout looks is covered in does EW pay a dividend?